Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Cash from Financing Activities (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Cash from Financing Activities for 12 consecutive years, with $40000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 33.33% year-over-year to $40000.0, compared with a TTM value of $170000.0 through Nov 2025, up 422.77%, and an annual FY2025 reading of $160000.0, up 481.56% over the prior year.
  • Cash from Financing Activities was $40000.0 for Q4 2025 at CNBX Pharmaceuticals, up from $30008.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.2 million in Q2 2021 and bottomed at $1259.0 in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $211608.0, with a median of $30008.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities tumbled 98.06% in 2024, then soared 2281.59% in 2025.
  • Year by year, Cash from Financing Activities stood at $1.2 million in 2021, then tumbled by 88.01% to $149858.0 in 2022, then plummeted by 83.32% to $24993.0 in 2023, then increased by 20.03% to $30000.0 in 2024, then soared by 33.33% to $40000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for CNBX at $40000.0 in Q4 2025, $30008.0 in Q3 2025, and $19992.0 in Q2 2025.